Yongfang Ma
Overview
Explore the profile of Yongfang Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Cao W, Zhang Y, Li A, Yu P, Song L, Liang J, et al.
Toxicol Mech Methods
. 2021 Jul;
31(8):589-599.
PMID: 34233590
Objective: Epithelial mesenchymal transition (EMT) and inflammation have been identified as carcinogenic agents. This study aims to investigate whether inhibition of trichloroethylene (TCE) associated hepatocellular carcinoma (HCC) by curcumin is...
22.
Cao W, Liu X, Zhang Y, Li A, Xie Y, Zhou S, et al.
Biomed Res Int
. 2021 May;
2021:5556306.
PMID: 33987439
Acquired resistance of hepatocellular carcinoma (HCC) to sorafenib (SFB) is the main reason for the failure of SFB treatment of the cancer. Abnormal activation of the PI3K/AKT/mTOR pathway is important...
23.
Xu R, Zhang Y, Li A, Ma Y, Cai W, Song L, et al.
Mol Med Rep
. 2021 May;
24(1).
PMID: 33982772
Liver cancer remains one of the leading causes of cancer deaths worldwide. The therapeutic effect of oxaliplatin on liver cancer is often limited by acquired resistance of the cancer cells....
24.
Ma Y, Xu R, Liu X, Zhang Y, Song L, Cai S, et al.
Int J Med Sci
. 2021 Feb;
18(6):1456-1464.
PMID: 33628103
Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma; vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit, and Flt-3 signaling, is approved for treatment of advanced hepatocellular carcinoma...
25.
Shen J, Cai W, Ma Y, Xu R, Huo Z, Song L, et al.
Nanoscale Res Lett
. 2020 Nov;
15(1):220.
PMID: 33242103
Delivery of tumor-specific inhibitors is a challenge in cancer treatment. Antibody-modified nanoparticles can deliver their loaded drugs to tumor cells that overexpress specific tumor-associated antigens. Here, we constructed sorafenib-loaded polyethylene...
26.
Liang Y, Xie C, Li A, Huo Z, Wu B, Cai S, et al.
J Biomed Nanotechnol
. 2020 Sep;
16(4):446-455.
PMID: 32970977
Aim: To assess AB-BEZ235-NP potential as a radio-sensitizer in hepatocellular carcinoma models. Method: By comparing hepatocellular carcinoma cell with simple radiation or combined AB-BEZ235-NP therapy, the HCC apoptosis and self-repair...
27.
Yuan Y, Liao H, Pu Q, Ke X, Hu X, Ma Y, et al.
Signal Transduct Target Ther
. 2020 Jun;
5(1):85.
PMID: 32528035
Radiotherapy remains one of the major treatments for non-small cell lung cancer (NSCLC) patients; whereas intrinsic or acquired radioresistance limits its efficacy. Nevertheless, most studies so far have only focused...
28.
Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, et al.
J Cancer Res Clin Oncol
. 2020 Apr;
146(7):1737-1749.
PMID: 32342201
Purpose: The usual first-line strategy of wild-type EGFR (wtEGFR) non-small cell lung cancer (NSCLC) remains cisplatin-based chemotherapy. However, cisplatin often loses effectiveness because most tumors acquire drug resistance over time....
29.
Tang X, Li A, Xie C, Zhang Y, Liu X, Xie Y, et al.
Nanoscale Res Lett
. 2020 Mar;
15(1):63.
PMID: 32219609
Polymer materials encapsulating drugs have broad prospects for drug delivery. We evaluated the effectiveness of polyethylene glycol-poly (lactic-co-glycolic acid) (PLGA-PEG) encapsulation and release characteristics of PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235). We...
30.
Liu X, Xie C, Li A, Zhang Y, Liu X, Zhou S, et al.
Am J Transl Res
. 2020 Jan;
11(12):7255-7271.
PMID: 31934276
Desensitization of hepatocellular carcinoma (HCC) to paclitaxel chemotherapy is a major deterrent to successful treatment of the cancer. Abnormal activation of the PI3K/Akt/mTOR, pathway is a common outcome of chemotherapy...